Characterization of leukemias with ETV6-ABL1 fusion

Haematologica

Volumn 101, Issue 9, 2016, Pages 1082-1093

  Zaliova, Marketa ^a   Moorman, Anthony V ^b   Cazzaniga, Giovanni ^c   Stanulla, Martin ^d   Harvey, Richard C ^e   Roberts, Kathryn G ^f   Heatley, Sue L ^g   Loh, Mignon L ^h   Konopleva, Marina ⁱ   Chen, I Ming ^e   Zimmermannova, Olga ^a   Schwab, Claire ^b   Smith, Owen ^j   Mozziconacci, Marie Joelle ^k   Chabannon, Christian ^k   Kim, Myungshin ^l   Frederik Falkenburg, J H ^m   Norton, Alice ⁿ   Marshall, Karen ^o   Haas, Oskar A ^p   Starkova, Julia ^a   Stuchly, Jan ^a   Hunger, Stephen P ^q   White, Deborah ^g   Mullighan, Charles G ^f   Willman, Cheryl L ^e   Stary, Jan ^a   Trka, Jan ^a   Zuna, Jan ^a   more..

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF NEW MEXICO   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^k INSTITUT PAOLI CALMETTES   (France)

^l The Catholic University of Korea   (South Korea)

^m LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^o UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^p ST ANNA CHILDREN S HOSPITAL   (Austria)

^q UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; NILOTINIB; TRANSCRIPTION FACTOR ETV6; ONCOPROTEIN; PROTEIN TYROSINE KINASE; TEL-ABL FUSION PROTEIN, HUMAN; TRANSCRIPTOME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER INCIDENCE; CELL PROLIFERATION; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CLUSTER ANALYSIS; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MALE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; ADOLESCENT; AGED; ALTERNATIVE RNA SPLICING; CHILD; GENE TRANSLOCATION; GENETICS; INFANT; LEUKEMIA; MIDDLE AGED; MORTALITY; PHENOTYPE; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALTERNATIVE SPLICING; CHILD; CHILD, PRESCHOOL; CLUSTER ANALYSIS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; LEUKEMIA; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-TYROSINE KINASES; TRANSCRIPTOME; TRANSLOCATION, GENETIC; YOUNG ADULT;

EID: 84986237322     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.144345     Document Type: Article

References (59)

1. Golub TR, Goga A, Barker GF, et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol. 1996; 16(8): 4107-4116.
2. Hannemann JR, McManus DM, Kabarowski JH, Wiedemann LM. Haemopoietic transformation by the TEL/ABL oncogene. Br J Haematol. 1998; 102(2): 475-485.
3. Okuda K, Golub TR, Gilliland DG, Griffin JD. p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene. 1996; 13(6): 1147-1152.
4. Million RP, Aster J, Gilliland DG, Van Etten RA. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice. Blood. 2002; 99(12): 4568-4577.
5. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol. 2009; 10(2): 125-134.
6. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009; 360(5): 470-480.
7. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Phlike acute lymphoblastic leukemia. N Engl J Med. 2014; 371(11): 1005-1015.
8. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012; 22(2): 153-166.
9. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCRABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997; 90(12): 4947-4952.
10. Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001; 97(8): 2440-2448.
11. Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood. 2010; 116(23): 4874-4884.
12. Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica. 2013; 98(11): e146-148.
13. van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCRABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood. 2013; 122(15): 2622-2629.
14. Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol. 2013; 31(25): e413-416.
15. Baeumler J, Szuhai K, Falkenburg JH, van Schie ML, Ottmann OG, Nijmeijer BA. Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement. Cancer Genet Cytogenet. 2008; 185(1): 37-42.
16. Malone A, Langabeer S, O’Marcaigh A, Storey L, Bacon CL, Smith OP. A doctor(s) dilemma: ETV6-ABL1 positive acute lymphoblastic leukaemia. Br J Haematol. 2010; 151(1): 101-102.
17. Mozziconacci MJ, Sainty D, Chabannon C. A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome. Am J Hematol. 2007; 82(7): 688-689.
18. Park J, Kim M, Lim J, et al. Variant of ETV6/ABL1 gene is associated with leukemia phenotype. Acta Haematol. 2013; 129(2): 78-82.
19. Yeung DT, Moulton DJ, Heatley SL, et al. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. Leukemia. 2015; 29(1): 230-232.
20. Zuna J, Zaliova M, Muzikova K, et al. Acute leukemias with ETV6/ABL1 (TEL/ABL) fusion: poor prognosis and prenatal origin. Genes Chromosomes Cancer. 2010; 49(10): 873-884.
21. Andreasson P, Johansson B, Carlsson M, et al. BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion. Genes Chromosomes Cancer. 1997; 20(3): 299-304.
22. Barbouti A, Ahlgren T, Johansson B, et al. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate. Br J Haematol. 2003; 122(1): 85-93.
23. Brunel V, Sainty D, Carbuccia N, et al. A TEL/ABL fusion gene on chromosome 12p13 in a case of Ph-, BCR-atypical CML. Leukemia. 1996; 10: 2003.
24. Gancheva K, Virchis A, Howard-Reeves J, et al. Myeloproliferative neoplasm with ETV6-ABL1 fusion: A case report and literature review. Mol Cytogenet. 2013; 6(1): 39.
25. Kawamata N, Dashti A, Lu D, et al. Chronic phase of ETV6-ABL1 positive CML responds to imatinib. Genes Chromosomes Cancer. 2008; 47(10): 919-921.
26. Kelly JC, Shahbazi N, Scheerle J, et al. Insertion (12;9)(p13;q34q34): A cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia. Cancer Genet Cytogenet. 2009; 192(1): 36-39.
27. Keung YK, Beaty M, Steward W, Jackle B, Pettnati M. Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet. 2002; 138(2): 139-142.
28. La Starza R, Trubia M, Testoni N, et al. Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. Haematologica. 2002; 87(8): 789-794.
29. Lin H, Guo JQ, Andreeff M, Arlinghaus RB. Detection of dual TEL-ABL transcripts and a Tel-Abl protein containing phosphotyrosine in a chronic myeloid leukemia patient. Leukemia. 2002; 16(2): 294-297.
30. Meyer-Monard S, Muhlematter D, Streit A, et al. Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript. Leukemia. 2005; 19(6): 1096-1099.
31. Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res. 2009; 33(8): 1144-1146.
32. O’Brien SG, Vieira SA, Connors S, et al. Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation. Blood. 2002; 99(9): 3465-3467.
33. Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. The novel activation of ABL by fusion to an ets-related gene, TEL. Cancer Res. 1995; 55(1): 34-38.
34. Perna F, Abdel-Wahab O, Levine RL, Jhanwar SC, Imada K, Nimer SD. ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition. Haematologica. 2011; 96(2): 342-343.
35. Song JS, Shin SY, Lee ST, Kim HJ, Kim SH. A cryptic ETV6/ABL1 rearrangement represents a unique fluorescence in situ hybridization signal pattern in a patient with B acute lymphoblastic leukemia. Ann Lab Med. 2014; 34(6): 475-477.
36. Tirado CA, Sebastian S, Moore JO, Gong JZ, Goodman BK. Molecular and cytogenetic characterization of a novel rearrangement involving chromosomes 9, 12, and 17 resulting in ETV6 (TEL) and ABL fusion. Cancer Genet Cytogenet. 2005; 157(1): 74-77.
37. Van Limbergen H, Beverloo HB, van Drunen E, et al. Molecular cytogenetic and clinical findings in ETV6/ABL1-positive leukemia. Genes Chromosomes Cancer. 2001; 30(3): 274-282.
38. Yamamoto K, Yakushijin K, Nakamachi Y, et al. Extramedullary T-lymphoid blast crisis of an ETV6/ABL1-positive myeloproliferative neoplasm with t(9;12)(q34;p13) and t(7;14)(p13;q11.2). Ann Hematol. 2014; 93(8): 1435-1438.
39. Zhou MH, Gao L, Jing Y, et al. Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia. Ann Hematol. 2012; 91(8): 1235-1243.
40. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994; 84(12): 4064-4077.
41. Choi HJ, Kim HR, Shin MG, et al. Spectra of chromosomal aberrations in 325 leukemia patients and implications for the development of new molecular detection systems. J Korean Med Sci. 2011; 26(7): 886-892.
42. Janssen JW, Ridge SA, Papadopoulos P, et al. The fusion of TEL and ABL in human acute lymphoblastic leukaemia is a rare event. Br J Haematol. 1995; 90(1): 222-224.
43. Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: A report from the Childrens Cancer Study Group. J Clin Oncol. 1989; 7(12): 1807-1815.
44. Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia. 2010; 24(2): 265-284.
45. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998; 352(9142): 1731-1738.
46. Pane F, Intrieri M, Quintarelli C, Izzo B, Muccioli GC, Salvatore F. BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations. Oncogene. 2002; 21(56): 8652-8667.
47. Million RP, Harakawa N, Roumiantsev S, Varticovski L, Van Etten RA. A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase. Mol Cell Biol. 2004; 24(11): 4685-4695.
48. Million RP, Van Etten RA. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood. 2000; 96(2): 664-670.
49. Moorman AV, Enshaei A, Schwab C, et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood. 2014; 124(9): 1434-1444.
50. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007; 446(7137): 758-764.
51. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008; 453(7191): 110-114.
52. Virely C, Moulin S, Cobaleda C, et al. Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia. Leukemia. 2010; 24(6): 1200-1204.
53. Williams RT, Roussel MF, Sherr CJ. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Ablinduced acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2006; 103(17): 6688-6693.
54. Ghazavi F, Clappier E, Lammens T, et al. CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol. Haematologica. 2015; 100(10): 1311-1319.
55. Iacobucci I, Ferrari A, Lonetti A, et al. CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. Clin Cancer Res. 2011; 17(23): 7413-7423.
56. Olsson L, Castor A, Behrendtz M, et al. Deletions of IKZF1 and SPRED1 are associated with poor prognosis in a population-based series of pediatric B-cell precursor acute lymphoblastic leukemia diagnosed between 1992 and 2011. Leukemia. 2014; 28(2): 302-310.
57. van der Veer A, Zaliova M, Mottadelli F, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood. 2014; 123(11): 1691-1698.
58. Roberts KG, Pei D, Campana D, et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol. 2014; 32(27): 3012-3020.
59. Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: Addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014; 123(6): 843-850.